AbbVie
ABBV
4,192 hedge funds and large institutions have $334B invested in AbbVie in 2026 Q2 according to their latest regulatory filings, with 284 funds opening new positions, 1,912 increasing their positions, 1,528 reducing their positions, and 111 closing their positions.
156% more first-time investments, than exits
New positions opened: 284 | Existing positions closed: 111
25% more repeat investments, than reductions
Existing positions increased: 1,912 | Existing positions reduced: 1,528
17% more capital invested
Capital invested by funds: $285B → $334B (+$48.9B)
17% more call options, than puts
Call options by funds: $3.71B | Put options by funds: $3.17B
14% more funds holding in top 10
Funds holding in top 10: 174 → 198 (+24)
2% more funds holding
Funds holding: 4,097 → 4,192 (+95)
1.7% more ownership
Funds ownership: 73.59% → 75.29% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.16B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$718M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$643M |
| 4 |
SG Americas Securities
New York
|
+$613M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$576M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.91B |
| 2 |
DAM
Diamant Asset Management
Ridgefield,
Connecticut
|
-$786M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$581M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$403M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$396M |
ABBV Hedge Fund Activity: Q2 2026 in Review
4,192 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2026, worth a combined $334B — up 17% from $285B a quarter earlier.
Buyers outnumbered sellers: 284 funds opened new ABBV positions and 111 closed out — a net gain of 173 holders — while 1,912 added to existing stakes and 1,528 trimmed.
The largest buyer was Franklin Resources, adding an estimated $1.16B. The largest seller was JP Morgan Chase, cutting an estimated $1.91B.
- 4,192 institutional investors held AbbVie (ABBV) as of Q2 2026, up from 4,097 in Q1 2026.
- Funds reported $334B of AbbVie stock for Q2 2026, up 17% quarter-over-quarter.
- 284 funds opened new AbbVie positions in Q2 2026 and 111 closed out, a net change of +173 holders.
- The largest AbbVie buyer in Q2 2026 was Franklin Resources, an estimated $1.16B added.
- The largest AbbVie seller in Q2 2026 was JP Morgan Chase, an estimated $1.91B sold.
Based on aggregated 13F filings for Q2 2026.